Abpro Corporation (NASDAQ: ABP) was founded in August 2004 and began commercial operations in May 2007. It was formerly known as IE LAB, Inc., and changed to its current name in September 2007. Its headquarters is located in Woburn, Massachusetts, USA, full-time With 42 employees (3/31/2018), it is a biotechnology company dedicated to the development of next-generation antibody therapeutics to save the lives of patients with severe life-threatening diseases and improve their quality of life.
Abpro Corporation (ABP):
Abpro Corporation focuses on novel antibody constructs in immuno-oncology, ophthalmology and autoimmunity. By using the company’s proprietary DiversImmune and MultiMab antibody discovery and engineering platforms, Abpro Corporation is developing a series of potential best-in-class antibodies independently or through collaborations with global pharmaceutical and research institutions (such as GlaxoSmithKline ).
The two main candidate products of Abpro Corporation are ABP-100 and ABP-201, which have the function of the company’s next-generation tetravalent antibody (TetraBi antibody format) and can bind to two different targets, each with two Different binding sites.
1. ABP-100 -designed to regulate the patient’s immune system by co-targeting human epidermal growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3), the co-receptor of T cells, to fight cancer. Abpro Corporation plans to develop ABP-100 for refractory HER2+ solid tumors, with a focus on orphan indications.
2. ABP-201 -aims to block blood vessel formation and normalize damaged blood vessels by co-targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2). The company plans to develop ABP-201 to treat ocular vascular diseases, focusing on diabetic macular edema (DME).
Abpro Corporation intends to track these two main product candidates from the perspective of a wide range of CD3 targeted T cell participants based on the differentiated format of ABP-100. Abpro Corporation has an exclusive license for the global commercialization rights of ABP-100 and ABP-201, and plans to initiate clinical trials of ABP-100 and ABP-201 in the first half of 2019 and the second half of 2019, respectively.
Abpro Corporation (ABP) investment:
Abpro Corporation (NASDAQ: ABP) submitted its IPO prospectus on 4/11/2018, and plans to IPO on NASDAQ on 5/11/2018, with an issue price of US$14.00-16.00, issuing 4 million shares, and raising funds not exceeding 73.6 million USD, stock code: ABP.